Electro-hyperthermia inhibits glioma tumorigenicity through the induction of E2F1-mediated apoptosis
/in Glioblastoma, Hyperthermia, International Publications /von 2015-09-14 / Int J Hyperthermia 2015;31(7):784-92Irradiation of necrotic cancer cells, employed for pulsing dendritic cells (DCs), potentiates DC vaccine-induced antitumor immunity against high-grade glioma
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-09-11 / Oncoimmunology 2016 Feb;5(2):e1083669Tumour Relapse Prediction Using Multiparametric MR Data Recorded during Follow-Up of GBM Patients
/in Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-08-27 / Biomed Res Int 2015;2015:842923Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-08-27 / J. Neurooncol. 2015 Oct;125(1):65-74Dendritic cell-based immunotherapy targeting Wilms‘ tumor 1 in patients with recurrent malignant glioma
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-08-07 / J. Neurosurg. 2015 Oct;123(4):989-97Phase I study of combination of antitumor immunotherapy targeted against cytomegalovirus (CMV) plus regulatory T-cell inhibition in patients with newly diagnosed glioblastoma multiforme (GBM).
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-06-17 / J Clin Oncol 33, 2015 (suppl; abstr e13030)Brain Tumor Immunotherapy: What have We Learned so Far?
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-06-17 / Front Oncol 2015;5:98Re-irradiation or re-operation followed by dendritic cell vaccination? Comparison of two different salvage strategies for relapsed high-grade gliomas by means of a new prognostic model
/in Dendritic Cells, Glioblastoma, International Publications, IOZK Veröffentlichungen /von 2015-06-13 / J. Neurooncol. 2015 Sep;124(2):325-32Comparative impact of treatment on clinical benefit in patients with glioblastoma (GBM) enrolled in the phase II trial of ICT-107.
/in Dendritic Cells, Glioblastoma, International Publications /von 2015-06-01 / J Clin Oncol 33, 2015 (suppl; abstr 2036)
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de